Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
Publication Title
Mult Scler Relat Disord
Document Type
Article
Publication Date
9-1-2019
Keywords
Adult; Alemtuzumab; Female; Humans; Immunologic Factors; Multiple Sclerosis, Relapsing-Remitting; Myocardial Infarction
Abstract
Alemtuzumab is an anti-CD52 monoclonal antibody used for the treatment of lymphoproliferative disorders and relapsing-remitting multiple sclerosis. We report a 30-year-old woman with relapsing-remitting multiple sclerosis who developed a type 2 non-ST elevated myocardial infarction (NSTEMI) during her first alemtuzumab infusion cycle. While acute coronary syndrome has been described with alemtuzumab in the treatment of lymphoma, alemtuzumab-associated cardiac ischemia in multiple sclerosis is uncommon and can occur in patients without cardiovascular risk factors.
Area of Special Interest
Neurosciences (Brain & Spine)
Area of Special Interest
Cardiovascular (Heart)
Specialty/Research Institute
Neurosciences
Specialty/Research Institute
Cardiology
